Abeona Therapeutics (NASDAQ:ABEO) Price Target Raised to $20.00

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) had its target price raised by equities research analysts at HC Wainwright from $15.00 to $20.00 in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective suggests a potential upside of 213.23% from the stock's current price. HC Wainwright also issued estimates for Abeona Therapeutics' Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.57 EPS.

A number of other equities analysts also recently issued reports on ABEO. Oppenheimer initiated coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an "outperform" rating and a $16.00 price target on the stock. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $18.75.

Abeona Therapeutics Stock Down 2.7 %

Shares of ABEO traded down $0.18 during mid-day trading on Wednesday, hitting $6.39. The company's stock had a trading volume of 1,100,380 shares, compared to its average volume of 561,700. The firm has a market capitalization of $311.59 million, a price-to-earnings ratio of -2.38 and a beta of 1.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.32. The company's 50-day moving average is $5.09 and its 200-day moving average is $5.60.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19. On average, equities research analysts forecast that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Insider Buying and Selling

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. The trade was a 1.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. Wellington Management Group LLP acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at about $520,000. Trexquant Investment LP purchased a new stake in Abeona Therapeutics in the 4th quarter worth approximately $382,000. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $84,000. JPMorgan Chase & Co. increased its holdings in shares of Abeona Therapeutics by 74.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock valued at $424,000 after purchasing an additional 28,606 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 21.7% in the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company's stock valued at $2,942,000 after purchasing an additional 83,050 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.